Ascendis Pharma A (ASND) Payables (2016 - 2026)

Ascendis Pharma A has disclosed Payables across 11 years of filings, most recently posting $616.7 million for Q1 2026.

• Payables for Q1 2026 came in at $616.7 million, up 9.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $616.7 million (up 9.81% YoY), and the FY2025 annual result was $605.4 million, up 2.15% from the prior year.
• Payables came in at $616.7 million for Q1 2026 at Ascendis Pharma A, up from $605.4 million in the prior quarter.
• In the past five years, Payables ranged from a high of $730.5 million in Q3 2023 to a low of $498.5 million in Q4 2022.
• The 5-year median for Payables is $592.6 million (2024), against an average of $596.8 million.
• Across the five-year window, Payables soared 1048.72% in 2022 and slipped 25.23% in 2024, its largest moves.
• Ascendis Pharma A's Payables stood at $498.5 million in 2022, then advanced by 8.28% to $539.8 million in 2023, then grew by 9.8% to $592.6 million in 2024, then grew by 2.15% to $605.4 million in 2025, then grew by 1.87% to $616.7 million in 2026.
• The last three Payables figures came in at $616.7 million (Q1 2026), $605.4 million (Q4 2025), and $590.2 million (Q3 2025), per Business Quant data.